IFNG and ovarian cancer: We observed a clear association of our gene signatures with favorable prognosis that was higher than for ovarian cancer: IFNG, CD30, CXCL13, and PRF1 (HR = 0.39; CI = 0.23–0.67; log rank p = 3E-04); IFNG, CD30, and CXCL13 (HR = 0.34; CI = 0.2–0.58; log rank p = 3.6E-05); IFNG, CD30, and PRF1 (HR = 0.54; CI = 0.33–0.9; log rank p = 0.015); IFNG, CXCL13, and PRF1 (HR = 0.39; CI = 0.23–0.66; log rank p = 0.00029); CD30, CXCL13 and PRF1 (HR = 0.39; CI = 0.23–0.67; log rank p = 3E-04) (Figure 5A).